Drugs / Droperidol
Droperidol
also known as
Dridol · DRO · Droleptan · Droperidol component of innovar · Inapsine · MCN-JR-4749 · NSC-169874 · R-4749 · +1 more
Small molecule targets HTR2A via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | INAPSINE | — | 1970-06-11 | fda.gov ↗ |
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07015528 | Sep 2025 → Aug 2026 overdue | — | Stanford University | Enrolling by invitation | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04411069 | Feb 2019 → Mar 2020 | — | Cancer Institute of the State of São Paulo | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05244460 | Dec 2021 → Jan 2023 | cannabinoid hyperemesis syndrome | Mercy Health Ohio | Unknown | No outcome recorded |
| Phase 3 | NCT02744495 | Feb → Nov 2016 | — | Hôpital Privé de Parly II - Le Chesnay | Completed | No outcome recorded |
| Phase 3 | NCT01765829 | Nov 2012 → Nov 2015 | psychotic disorder | Fundación Pública Andaluza Progreso y Salud | Unknown | No outcome recorded |
| Phase 3 | NCT01432977 | Sep 2011 → Jun 2012 | pain agnosia | University Hospital, Limoges | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05068180 | Oct 2021 → Apr 2022 | arthropathy, disease of bone structure, female reproductive organ cancer, gastric neoplasm +6 | RenJi Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00702442 | Jun 2008 → Jul 2011 | — | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase 4 | NCT00445055 | Apr 2007 → Apr 2009 | — | University Hospital, Bordeaux | Terminated | No outcome recorded |
| Phase 4 | NCT00209885 | Oct 2005 → ? | cholecystolithiasis | Hvidovre University Hospital | Unknown | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT05401058 | Nov 2022 → Dec 2024 | digestive system disorder, female reproductive system disorder, urinary system disorder | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT03944681 | Apr 2019 → Dec 2020 | — | Medical University of Gdansk | Completed | No outcome recorded |
| — | NCT01406860 | Jul 2011 → Jul 2012 | headache disorder | University of Iowa | Terminated | No outcome recorded |
| — | NCT01739985 | Dec 2010 → Jul 2013 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
Also used as a comparator or background therapy in 14 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02858310 Background | Jan 2017 → Jul 2025 | cervical intraepithelial neoplasia, human papilloma virus infection, in situ carcinoma, vulvar neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05065567 Comparator | Aug 2021 → Nov 2023 | cyclic vomiting syndrome | Corewell Health South | Terminated | No outcome recorded |
| Phase 3 | NCT01942343 Comparator | Oct 2013 → Oct 2015 | drug-induced akathisia | University Hospital, Strasbourg, France | Completed | No outcome recorded |
| Phase 3 | NCT01679093 Comparator | Jun 2009 → Jan 2011 | — | University Hospital, Lille | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT05172739 Comparator | Oct 2021 → Nov 2025 overdue | chronic pain syndrome, non-small cell lung carcinoma, substance-related disorder | University of Crete | Recruiting | No outcome recorded |
| Phase 4 | NCT04894864 Comparator | Oct 2020 → Sep 2026 expected | abdominal aortic aneurysm | University of Crete | Recruiting | No outcome recorded |
| Phase 4 | NCT02282956 Background | Oct 2014 → Feb 2017 | — | Dr.med. Sabine Schoenfeld | Unknown | No outcome recorded |
| Phase 4 | NCT01819857 Comparator | Jun 2011 → Jul 2013 | early repolarization associated with ventricular fibrillation | Medical University of Gdansk | Completed | No outcome recorded |
| Phase 4 | NCT01434017 Comparator | Nov 2008 → Jun 2013 | — | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07480785 Background | Jan 2026 → Oct 2027 expected | gallstones, leiomyoma, ovarian neoplasm | Zhejiang University | Recruiting | No outcome recorded |
| — | NCT03023462 Comparator | Sep 2019 → Jun 2020 | — | Ostfold Hospital Trust | Completed | No outcome recorded |
| — | NCT03677323 Comparator | Jan → Feb 2019 | toe, misshapen | Clinique Saint Jean, France | Completed | No outcome recorded |
| — | NCT02625181 Background | Jul 2016 → Nov 2017 | — | Vanderbilt University | Completed | No outcome recorded |
| — | NCT00624208 Comparator | Feb 2008 → Aug 2009 | early repolarization associated with ventricular fibrillation | University of British Columbia | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Droperidol | “Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine,...” NCT01765829 ↗26“Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk...” NCT02744495 ↗ “Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.” NCT05068180 ↗ “Dexamethasone 5mg and palonosetron 0.25mg i.v. will be given after induction, and droperidol 1.25 mg i.v. will be given during the abdominal closure.” NCT07480785 ↗ “intravenous administration of 0.625 mg droperidol” NCT01819857 ↗ “Ondansetron 4mg or Droperidol 0.625mg” NCT04894864 ↗ “Ondansetron or Droperidol” NCT05172739 ↗ |
| Known as | Dridol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1108 ↗ |
| Known as | DRO | “The combination of dexamethasone (DEX), ondansetron (OND) and droperidol (DRO) is efficacious in preventing postoperative nausea and vomiting in adults, but has not been well...” PMID 28505233 ↗ Jun 2017 |
| Known as | Droleptan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03677323 ↗ |
| Known as | Droperidol component of innovar | ChEMBL registry synonym — accepted as the source's own label CHEMBL1108 ↗ |
| Known as | Inapsine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1108 ↗ |
| Known as | MCN-JR-4749 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1108 ↗ |
| Known as | NSC-169874 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1108 ↗ |
| Known as | R-4749 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1108 ↗ |
| Known as | Xomolix | “Droperidol (Xomolix, Kyowa Kirin) 1.25 mg i.v. bolus” NCT03944681 ↗ |
| Action | Inhibit | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL1108 ↗ |
| Modality | Small molecule | — CHEMBL1108 ↗ |
| Route | Intravenous | “Intravenous injection of 0,625 mg Droperidol, 30 min before the end of anesthesia” NCT00445055 ↗ |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL1108 ↗ |